

**BAUSCH+LOMB**



**TEACH-IN**

**SERIES**

**BL1107**

FIRST GLAUCOMA THERAPY TO  
IMPROVE VISUAL FUNCTION  
THROUGH NEUROPROTECTION

---

**ELIOS**

FIRST CLINICALLY VALIDATED  
IMPLANT-FREE MIGS  
EXCIMER LASER

# Disclaimers

## Forward-Looking Statements

This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements our focus on pipeline innovation, the success of our pipeline products and R&D programs, the existence of potential game changers in our pipeline and our ability to be the best in class or first product to market of its kind, anticipated approval and launch dates for our pipeline products, our estimates for potential peak sales for our pipeline products, our ability to outperform the market, our ability to expand into new categories and new and existing markets and to address new indications and disease states, the expected market acceptance and performance for certain of our pipeline products, the expected market size for certain of the markets in which we expect to have products, and the timing of commencement and completion of clinical studies and other development work. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "predicts," "projects," "goals," "intends," "plans," "should," "could," "would," "may," "might," "will," "strive," "believes," "estimates," "potential," "target," "commit," "forecast," "outlook," "guidance," "tracking," or "continue" and positive and negative variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators (the "CSA") (including the Company's Annual Report on Form 10-K for the year ended December 31, 2025 (which was filed with the SEC and CSA on February 18, 2026) and its most recent quarterly filings), which factors are incorporated herein by reference. They also include risks relating to the development of our pipeline products, including the risk that our studies may not produce successful results or demonstrate safety and efficacy in humans, risks that our pre-clinical and clinical trials may be delayed (which, in turn, may delay the launch of these products) and risks that the regulatory approval of our products may be lengthy, costly and, ultimately, not successful. They also include risks relating to the launch and commercialization of our products, including risks relating to the costs, required resources and unpredictability of commercial launches, risks that our products may not achieve the anticipated levels of market acceptance, which can result from a number of factors, many of which are outside of our control, risks that our products may experience negative publicity or reputational harm, competitive risks, such as our competitors beating us to market or developing new or better technologies and risks that we may face supply interruptions with our finished products or components thereof, which, in turn, may impact our ability to successfully launch or commercialize our products. They also include the expected impact of the tariffs imposed by the U.S. and counter-tariffs or other retaliatory measures imposed on the U.S. by other countries and disruptions to global supply chains and other potential results as a result of these developments and our ability to successfully manage the expected impact of such tariffs and counter-tariffs and other

measures, including the success of our planned actions and levers to manage these matters. Finally, they also include, but are not limited to, risks and uncertainties caused by or relating to a potential recession and other adverse economic conditions (such as heightened inflation and interest rates, fluctuations in exchange rates, imposition of and adverse changes to tariffs, duties and other trade protection measures and slower growth), which could adversely impact our revenues, expenses and resulting margins. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including the assumption that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements.

References in this presentation to future launch dates refer to the anticipated launch dates for the applicable product, based on management's estimates taking into account, among other things, the current stage of the development or regulatory pathway of such products, typical development, regulatory and launch timelines for similar products and assumptions regarding sufficient supply availability for launch purposes. In addition, unless otherwise indicated, references in this presentation to peak sales refer to the potential peak annual sales of the applicable product, based on management's estimates, taking into account, among other things, sales of similar products.

Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law.



## **Yehia Hashad, MD**

*Executive Vice President,  
R&D & Chief Medical Officer*



## **Mayssa Attar, Ph.D.**

*Senior Vice President,  
Pharmaceuticals and Consumer R&D*




## **Kelly Swaim, MD**

*Senior Vice President,  
Surgical R&D*





**Cathleen McCabe, MD,** *Strategic Medical Advisor, Bausch + Lomb*

# Advancing Robust Pipeline in 2026<sup>1</sup>




# What We Know About Glaucoma

## Pathophysiology



## Therapeutic Intervention



# No Glaucoma Therapeutic Exists to Treat the Vision Threatening Neurodegenerative Pathology



**4.2M**

individuals in U.S.  
have glaucoma<sup>1</sup>

**35%**

of patients with  
glaucoma have  
vision-affecting  
glaucoma<sup>1</sup>

---

Early neuroprotection for patients with  
glaucoma holds the promise of decreasing the  
percentage that go on to experience vision loss

# $\alpha$ 2-Adrenergic Agonists to Treat Glaucoma Pathology

- 

1 Activation of  $\alpha$ 2-adrenergic receptors modulates the sympathetic nervous system by limiting neurotransmitter release eg norepinephrine (stress)
- 


2  $\alpha$ 2-adrenergic agonist drugs harness this endogenous role
- 

3 In glaucoma,  $\alpha$ 2-adrenergic agonists may help preserve visual function by mitigating neurodegenerative stress
- 


4 Through broad dampening of neurodegenerative pathways,  $\alpha$ 2-adrenergic signaling may promote neuronal survival and function
- 

5 These beneficial effects are relevant to multiple retina cell types

## Disease Pathways Leading to Neurodegeneration<sup>1</sup>



# Addressing Neurodegenerative Vision Loss in Glaucoma



Glaucoma is a **neurodegenerative disease** with loss of retinal ganglion cells and optic nerve injury



Studies show most patients with mild to moderate glaucoma have **macular damage** and **vision complaints under low luminance**<sup>1,2</sup>



**No approved therapeutics to treat vision loss** associated with glaucoma



**Brimonidine-treated glaucoma patients were less likely to develop visual field loss** compared to timolol even when IOP was decreased to the same extent.<sup>3</sup> Brimonidine is an **alpha2 adrenergic receptor ( $\alpha 2AR$ ) agonist**





**Mechanisms  $\alpha 2AR$  agonists improve vision:**

1. Neurofunctional enhancement (improve vision in days to weeks)
2. Neuroprotection (protect from vision-loss over months)

# BL1107 is Designed to Target Vision-Threatening Disease<sup>1</sup>

Prodrug *drives* tissue penetration



## Next-Generation α2B AR Agonist



Molecular attributes to target vision-threatening disease

Better penetration to retina


More potent and selective agonism of relevant receptor




Rapidly improve vision via neurofunctional enhancement and long-term preserve vision via neuroprotection

Selective and potent α2B agonism


### EC50<sup>2</sup> (Alpha2A)



### EC50<sup>2</sup> (Alpha2B)



α2B is widely expressed in retina & mediates beneficial effects on neuronal function<sup>3</sup>




Enhanced retinal penetration combined with selective and potent α2B agonism should maximize vision benefits

# Active BL1107 Attenuates Blue Light Induced Neurodegenerative Damage<sup>1</sup>


## Retinal Degeneration Model

- High-energy blue light–induced phototoxicity in rats serves as a model of neurodegenerative stress in the eye.
- Effects are assessed with and without the BL1107 active drug.


### Structural Effects



### Functional Effects<sup>2</sup>




## Structural Measure: SD-OCT



**BL1107 active drug preserves retinal structure following a blue light challenge.**


## Functional Measure: Scotopic b-wave ERG




**BL1107 active drug preserves retinal signaling following a blue light challenge.**

# Clinical POC: BL1107 Improves Vision in Glaucoma

## LL-BCVA $\geq$ 15-Letter Gain<sup>1</sup>



## Treatment Difference in Mean CFB at Day 14 in VF MD<sup>1</sup>



### Comparing patients treated with BL1107 to timolol:

- Greater proportion experienced  $\geq$ 15-letter gain in LL-BCVA
- Statistically significant improvement in VF MD




Ongoing larger Phase 2 study powered to demonstrate visual neuroenhancement effects is anticipated to readout 2H26<sup>2</sup>. These data will guide Phase 3 study design.

# BL1107 Phase 2 Study<sup>1</sup>



Randomized, double-masked, parallel group study of approximately 159 adult participants with POAG<sup>2</sup> or OHT<sup>3</sup> to assess the safety, ocular tolerability, and efficacy of topical ophthalmic BL1107 low and high dose versus timolol



Phase 2 study designed to replicate POC<sup>8</sup> results with refined study design elements

# BL1107 Robust Future Opportunities<sup>1</sup>



1

Phase 2 study anticipated to read out 2H26, targeting Phase 3 in 2027



2

Exploring indication expansion opportunities for BL1107



3

Ongoing efforts to develop intraocular sustained release BL1107 formulation


# Key Takeaways<sup>1</sup>

No current glaucoma therapies address the underlying neurodegenerative pathology that threatens vision

BL1107 has the potential to **establish a completely new class of glaucoma treatment** as the first therapy with a neuro-enhancement mechanism

Clinical proof-of-concept study has shown that **BL1107 improves vision in glaucoma patients**, and an ongoing Phase 2 trial is expected to read out in 2H26

# MIGS<sup>1</sup> Principles



High safety profile

Minimal disruption of normal anatomy

Ab interno approach

Meaningful IOP<sup>2</sup> lowering effect

Ease of use for patients and physicians

# Elios is Positioned to Expand MIGS Market<sup>1,2</sup>

~20%

of patients  
undergoing  
cataract surgery  
have POAG / OHT<sup>3</sup>

<50%

cataract surgeons  
are performing  
MIGS today<sup>4</sup>



elios

The first clinically-validated  
excimer laser MIGS

Glaucoma intervention  
combined with cataract surgery



# Highly Precise, Implant-Free Approach

## Excimer Laser Technology

Precise tissue ablation and minimal heat generation vs. SLT<sup>1</sup> that targets and selectively heats pigmented cells

## Optimal Flow Mechanics

Ten 210- $\mu\text{m}$  “microchannels” created in the TM<sup>2</sup> to decrease restrictive outflow, more than other MIGS

## Implant-Free

Reduced risk of poor placement or secondary surgical intervention to address misplacement

## Trabecular Meshwork Intact

Minimal tissue disruption to preserve biomechanics and physiological aqueous flow

## Broadly Adoptable

Rapid learning curve for surgeons familiar with placing linear devices into the angle

## Further Interventions Possible


Filtration surgeries, tube shunts, goniotomies, and cyclodestructive procedures remain options for refractory cases

# Positive Data from Pivotal U.S. Study<sup>1</sup>

Primary endpoints met, demonstrating statistically significant and clinically meaningful IOP<sup>2</sup> reduction


## Lowers IOP at 2 Years

IOP reduction by  $\geq 20\%$ <sup>3</sup> | 7.4 mmHg decrease in IOP



## Reduces Medication Burden at 2 Years

82% of patients were medication free



*Strong data from U.S. study reinforces clinically validated 8 years of follow-up data from Europe*

# Key Takeaways<sup>1</sup>

Elios is **positioned to expand the MIGS<sup>2</sup> market** by providing a glaucoma intervention that can be performed in conjunction with cataract surgery

<50% cataract surgeons are performing MIGS today<sup>3</sup>

First clinically validated excimer laser for MIGS, offering a **highly precise, implant-free approach**. Expect U.S. approval in 2H26

# Potential *Game Changers* in Glaucoma<sup>1</sup>

## BL1107

FIRST GLAUCOMA THERAPY TO  
IMPROVE VISUAL FUNCTION  
THROUGH NEUROPROTECTION

Phase 2 Data: 2H26<sup>2</sup>  
Initiate Phase 3: 2027<sup>2</sup>

Potential Peak Sales:  
~\$0.8B

## elios

FIRST CLINICALLY  
VALIDATED IMPLANT-FREE  
MIGS<sup>3</sup> EXCIMER LASER



Launch Date: 2H26 in U.S.<sup>2</sup>  
Commercialized in Europe

Potential Peak Sales:  
~\$175M